Needham analyst Michael Matson assigned a Buy rating to Cardiovascular Systems (CSII) today and set a price target of $50.00. The company’s shares closed last Tuesday at $37.62.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 15.5% and a 66.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.
Currently, the analyst consensus on Cardiovascular Systems is a Strong Buy with an average price target of $48.25, implying a 29.4% upside from current levels. In a report issued on May 7, Oppenheimer also maintained a Buy rating on the stock with a $48.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $48.28 and a one-year low of $27.70. Currently, Cardiovascular Systems has an average volume of 190.2K.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSII in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN.
Read More on CSII:
